Dr Narendra Saini SARS-CoV-2,Covid 19,Update
Chandigarh sunita shastri:
Dr Narendra Saini SARS-CoV2,Covi19,update Covid19
Total Worlwide Cases 38,363,600 deaths:1,090,811
US –Cases 8,090,253 deaths 220,873
India – Cases 7,239,389 deaths :110,617
Brazil -cases 5,114,823 deaths 151,063
Technological advances over the last century have made it possible from using convalescent serum to the utilization of recombinant fully human antibodies.To genetically humanize the immune system of mice has provided an efficient source of naturally selected, fully human antibodies. These manufactured copies in lab to mimic the human body’s natural antibodies.
In COVID-19 infection researchers evaluated antibodies produced by people who had recovered from and they selected pairs of antibodies that could simultaneously bind to different parts of the receptor binding domain of the SARS-CoV-2 spike protein.These monoclonal antibodies in experimental studies reduced viral load and alleviate symptoms in patients with COVID-19.These can be therapeutic substitute for the naturally-occurring immune response.Regeneron Pharmaceuticals, Inc. have made REGN-COV2 cocktail antibodies in lab which is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to inhibit the infectivity of SARS-CoV-2 by blocking the different part of spike protein of virus.
These antibodies can be delivered to people via injection, providing “passive immunity” and protection from the disease immediately, though they must be re-administered to remain effective over time till body develop its own immunity to infection.According to Regeneron,the company provided a single 8-gram dose of REGNCOV2, for use by the US President Trump
